Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2000
12/28/2000CA2374760A1 Quickly disintegrating solid preparations
12/28/2000CA2374548A1 Biologically active materials
12/28/2000CA2374002A1 Topical ophthalmic mast cell stabilizers for treating allergic eye diseases
12/28/2000CA2373921A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
12/28/2000CA2373497A1 Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
12/28/2000CA2371931A1 Steroid solution aerosol products with enhanced chemical stability
12/28/2000CA2371924A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
12/28/2000CA2341542A1 .alpha.1b-adrenergic receptor antagonists
12/27/2000EP1063293A2 Transforming growth factor alpha H1
12/27/2000EP1063254A1 Copolymers for the transport of nucleic acids in the cell
12/27/2000EP1063241A1 Pharmaceutical preparations comprising thioctic acid or dihydrolipoic acid in the form of inclusion compounds with cyclodextrins oder cyclodextrin derivatives and in the form of granulates, chewing-or effervescent tablets
12/27/2000EP1063235A1 Benzofurylpyrone derivatives
12/27/2000EP1063234A2 Hydrophobic taxane derivates
12/27/2000EP1063230A1 Cyclic amino compounds
12/27/2000EP1063228A1 Cycloalkene derivatives, process for producing the same, and use
12/27/2000EP1062954A1 Process for producing glycolytic metabolism regulators
12/27/2000EP1062951A1 Preventive and therapeutic agent for fatty liver
12/27/2000EP1062950A2 1,3 Oxathiolane nucleoside analogues
12/27/2000EP1062949A1 IgE ANTIBODY PRODUCTION INHIBITORS AND AUTOIMMUNE DISEASES INHIBITORS
12/27/2000EP1062948A1 Remedies for cardiac dilastolic disorders
12/27/2000EP1062947A1 Remedies for aids
12/27/2000EP1062946A1 Preventives and remedies for intestinal mucosal disorder
12/27/2000EP1062871A1 Bactericides
12/27/2000EP1062509A2 Methods and compositions for diagnosis of rheumatoid arthritis
12/27/2000EP1062362A1 Levo-monosaccharide in a nucleoside analog for use as an antiretroviral agent
12/27/2000EP1062339A2 Human fgf gene and gene expression products
12/27/2000EP1062336A1 Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
12/27/2000EP1062330A2 Ribozymes capable of inhibiting the expression of the ccr5 receptor
12/27/2000EP1062328A1 Suicide gene therapy system for the treatment of brain tumours
12/27/2000EP1062264A2 Enzyme inhibitors
12/27/2000EP1062261A1 Sulfonated comb polymers and preparations, especially hair cosmetic preparations based on such sulfonated comb polymers
12/27/2000EP1062232A2 Molecules that home to various selected organs or tissues
12/27/2000EP1062226A1 High affinity nucleic acid ligands of complement system proteins
12/27/2000EP1062225A1 REPLICATIVE HELICASE dnaB OF $i(STAPHYLOCOCCUS AUREUS)
12/27/2000EP1062223A1 Composition containing a precursor capable of being hydrolysed by glucocerebrosidase
12/27/2000EP1062222A1 Serine peptidase modulators
12/27/2000EP1062218A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
12/27/2000EP1062216A1 Inhibitors of phospholipase a2
12/27/2000EP1062215A1 Antagonists of gonadotropin releasing hormone
12/27/2000EP1062214A1 Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce tnfa levels
12/27/2000EP1062212A1 Heterocyclyl anthracyclinone derivatives
12/27/2000EP1062210A1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
12/27/2000EP1062209A1 Metabolically inert anti-inflammatory and anti-tumor antifolates
12/27/2000EP1062207A1 9-aminoacridine derivatives and process for the preparation thereof
12/27/2000EP1062206A2 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis
12/27/2000EP1062205A2 Inhibitors of phospholipase enzymes
12/27/2000EP1062204A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1062202A1 Cytostatic agents
12/27/2000EP1062201A2 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
12/27/2000EP1062199A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1061963A1 Protease inhibitors in absorbent articles
12/27/2000EP1061962A1 Disposable absorbent article having a skin care composition containing an enzyme inhibitor
12/27/2000EP1061955A1 Polynucleotide composition, method of preparation, and use thereof
12/27/2000EP1061953A1 Analgesic combination comprising nmda receptor antagonists and narcotic analgesics
12/27/2000EP1061952A2 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
12/27/2000EP1061942A1 Topical composition containing human epidermal growth factor
12/27/2000EP1061936A1 Cyclic dipeptides and azetidinone compounds and their use in treating cns injury and neurodegenerative disorders
12/27/2000EP1061934A1 Fibrinogen receptor antagonists
12/27/2000EP1061929A1 Pharmaceutical composition based on natural synthesis progesterone and oestradiol and preparation method
12/27/2000EP1061928A2 New contraceptive kit
12/27/2000EP1061927A1 Composition for reducing serum cholesterol levels
12/27/2000EP1061926A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists
12/27/2000EP1061925A1 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist
12/27/2000EP1061924A1 Treatment of compulsive behaviours in man and animals
12/27/2000EP1061923A2 Metal chelators for use in the treatment of alzheimer's disease
12/27/2000EP1061922A1 USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS
12/27/2000EP1061921A1 Vitronectin receptor antagonists
12/27/2000EP1061920A1 Pharmaceutical formulation comprising a 2[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
12/27/2000EP1061919A1 Novel opiate compounds, methods of making and methods of use
12/27/2000EP1061918A1 Controlled release composition of (1-azabicyclo(2.2.2)oct-3-yl)acetonitrile monohydrochloride
12/27/2000EP1061917A1 Methods of inhibiting bone resorption
12/27/2000EP1061916A2 Use os nitrone compounds for the inhibition of angiogenesis
12/27/2000EP1061915A1 Pharmaceutical formulations of taxanes
12/27/2000EP1061914A1 Lipoic acid analogs
12/27/2000EP1061913A2 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
12/27/2000EP1061912A1 Phenanthrofuran derivatives
12/27/2000EP1061911A2 Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are affected
12/27/2000EP1061910A1 Use of alpha-rar antagonists for inhibition of mucin secretion
12/27/2000EP1061909A1 Keto acid salts and amine derivatives, and their use for preparing medicines
12/27/2000EP1061908A1 Combination therapy and composition for acute coronary ischemic syndrome and related conditions
12/27/2000EP1061907A1 Monoterpenoid derivatives for treatment of cancer
12/27/2000EP1061906A1 Monolithic tablet for controlled drug release
12/27/2000EP1061901A1 Nicotine inhaler
12/27/2000EP1061887A1 Novel use of phospholipids of vegetable and animal origin in nutritional therapy
12/27/2000EP1061873A1 Use of corneal hardening agents in enzyme orthokeratology
12/27/2000EP1061816A1 Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
12/27/2000EP1061812A1 Food products having enhanced cocoa polyphenol content and processes for producing same
12/27/2000EP1061805A1 Regulation of endogenous gene expression in cells using zinc finger proteins
12/27/2000EP1061803A1 Novel compositions of eprosartan
12/27/2000EP1061802A1 Topical carbamazepine formulations and methods of use
12/27/2000EP1022278A4 Tetracyclical derivatives from pyrimidine
12/27/2000EP1021180A4 Mixed cyanoacrylate ester compositions
12/27/2000EP0891322B1 Dimethyl-substituted cyclohexane diene derivatives
12/27/2000EP0882015B1 Diphenyl stilbenes as prodrugs to cox-2 inhibitors
12/27/2000EP0833619B1 Controlled release of drugs delivered by sublingual or buccal administration
12/27/2000EP0832054B1 Heterocyclic methyl free radicals as image enhancing agents
12/27/2000EP0823900B1 Quinazoline derivatives
12/27/2000EP0821671B1 Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
12/27/2000EP0821666B1 Derivatives of succinamide and their use as metalloproteinase inhibitors
12/27/2000EP0791065B1 Protein targeting into hiv virions based on hiv-1 vpr fusion molecules
1 ... 6185 6186 6187 6188 6189 6190 6191 6192 6193 6194 6195 6196 6197 6198 6199 6200 6201 6202 6203 6204 6205 ... 7860